Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder

TY - JOUR

T1 - Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder

AU - Banaschewski, Tobias

AU - Soutullo, César

AU - Lecendreux, Michel

AU - Johnson, Mats

AU - Zuddas, Alessandro

AU - Hodgkins, Paul

AU - Adeyi, Ben

AU - Squires, Liza A.

AU - Coghill, David

PY - 2013

Y1 - 2013

N2 - Optimal management of attention deficit hyperactivity disorder (ADHD) aims not only to ameliorate patients' symptoms, but also to improve health-related quality of life (HRQL) and functioning. A pivotal, 7-week, randomized, double-blind, placebo-controlled, phase III study in children and adolescents in ten European countries demonstrated that the stimulant prodrug lisdexamfetamine dimesylate (LDX) is an effective and generally well-tolerated treatment for symptoms of ADHD.

AB - Optimal management of attention deficit hyperactivity disorder (ADHD) aims not only to ameliorate patients' symptoms, but also to improve health-related quality of life (HRQL) and functioning. A pivotal, 7-week, randomized, double-blind, placebo-controlled, phase III study in children and adolescents in ten European countries demonstrated that the stimulant prodrug lisdexamfetamine dimesylate (LDX) is an effective and generally well-tolerated treatment for symptoms of ADHD.

U2 - 10.1007/s40263-013-0095-5

DO - 10.1007/s40263-013-0095-5

M3 - Article

C2 - 23893527

SN - 1179-1934

JO - CNS Drugs

JF - CNS Drugs

ER -